Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionAngiogenesis inhibitor mAb
Molecular Target
Mechanism of ActionAngiogenesis inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat neovascular age-related macular degeneration (AMD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today